Since the mutational analysis of all the genes associated with HR pathways is increasingly complex,46 genomic scar analysis is believed to be more efficient in identifying “BRCA‐like” tumours and has thus been developed to discriminate between HR‐proficient and HR‐deficient tumours.46, 77, 78 Genomic scar analysis with methods such as the “MyChoice” test from Myriad Genetics and the “FoundationFocus” test from Foundation Medicine has been intensively evaluated in clinical trials of PARP inhibitors. The gene discussed is PARP1; the disease is neoplasm.